119th Congress · introduced in the House · Apr 8, 2025
Destruction of Hazardous Imports Act
Official title from Congress.gov
Latest action (Jul 21, 2026): Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Reported to House (Jun 18, 2026)
Destruction of Hazardous Imports Act
This bill expands the Food and Drug Administration’s (FDA’s) authority to require the destruction of certain items that are refused import into the United States and pose a risk to public health.
Under current law, imported food, drugs, medical devices, tobacco products, and cosmetics are subject to FDA review. If an imported item is deficient in a specified manner (e.g., counterfeit, misbranded, or manufactured under insanitary conditions), the item is generally refused admission to the United States. An item refused admission may generally be exported, except that the FDA may destroy a drug, medical device, or tobacco product that is valued under $2,500 without the opportunity for export.
Under the bill, the FDA may order the destruction, without the opportunity for export, of any food, drug, medical device, tobacco product, or cosmetic that is refused admission if the item presents a significant public health concern. If such an order is issued, the item’s owner or consignee must destroy it within 90 days at their own cost.
The bill also prohibits the unauthorized movement (e.g., export) of an item subject to a destruction order. A violator is subject to a fine, a prison term of up to one year, or both.
The FDA must promulgate regulations to carry out these provisions. These regulations must provide for due process for the owner or consignee of an item subject to a destruction order, including notice and an opportunity to appear before the item is destroyed.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4637-4638)
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4637-4638)
DEBATE - The House proceeded with forty minutes of debate on H.R. 2715.
Considered under suspension of the rules. (consideration: CR H4637-4639)
Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
Placed on the Union Calendar, Calendar No. 613.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-705.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-705.
Ordered to be Reported (Amended) by the Yeas and Nays: 43 - 0.
Committee Consideration and Mark-up Session Held
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote.
Subcommittee Consideration and Mark-up Session Held
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Administrative law and regulatory procedures · Consumer affairs · Customs enforcement · Department of Health and Human Services · Health promotion and preventive care · Product safety and quality · State and local government operations
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsIntroduced in House
Introduced in House
Actions from Congress.gov, newest first.
Coverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
7 citations.
NOVO NORDISK, INC. · lobbying firm or registrant: THE NICKLES GROUP, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$80,000
Paid to lobbying firm
Issues related to compounding and counterfeit drugs. H.R. 2715, Destruction of Hazardous Imports Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SOUTHERN SHRIMP ALLIANCE · lobbying firm or registrant: PICARD KENTZ & ROWE LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Sep 23, 2026 · issue area: Food Industry (safety, labeling, etc.)
$45,000
Paid to lobbying firm
S.3213/H.R.2715 - Destruction of Hazardous Imports Act, authorizes FDA to destroy regulated adulterated imports posing a significant public health concern, rather than allowin…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC · lobbying firm or registrant: COVINGTON & BURLING LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$220,000
Paid to lobbying firm
…sion draft); amendments to the National Childhood Vaccine Injury Act of 1986 and the Vaccine Injury Compensation Program; Destruction of Hazardous Imports Act (H.R. 2715); potential amendments to drug country of origin labeling requirements (discussion draft).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL CONFECTIONERS ASSOCIATION · lobbying firm or registrant: FIERCE GOVERNMENT RELATIONS
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$50,000
Paid to lobbying firm
H.R.2715 - The Destruction of Hazardous Imports Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NOVO NORDISK, INC. · lobbying firm or registrant: THE NICKLES GROUP, LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$80,000
Paid to lobbying firm
Issues related to compounding and counterfeit drugs. H.R. 2715, Destruction of Hazardous Imports Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SOUTHERN SHRIMP ALLIANCE · lobbying firm or registrant: PICARD KENTZ & ROWE LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Food Industry (safety, labeling, etc.)
$45,000
Paid to lobbying firm
S.3213/H.R.2715 - Destruction of Hazardous Imports Act, authorizes FDA to destroy regulated adulterated imports posing a significant public health concern, rather than allowin…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SOUTHERN SHRIMP ALLIANCE · lobbying firm or registrant: PICARD KENTZ & ROWE LLP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 18, 2026 · issue area: Food Industry (safety, labeling, etc.)
$45,000
Paid to lobbying firm
S.3213 and H.R.2715 - Destruction of Hazardous Imports Act, authorizes FDA to destroy regulated adulterated imports (including food) posing a significant public health concern, ra…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing